Stocks · News reference

8-K filing — ALX ONCOLOGY HOLDINGS INC (ALXO)

Oct 15, 2026, 8:55 PMSEC EDGAR

Filed: 2026-10-15 AccNo: 0001193125-26-422992 Size: 460 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ALXO

Source: edgar
Observed: Oct 15, 2026, 8:55 PM
Checked: Oct 15, 2026, 8:55 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 28, 2026, 12:03 PMBenzinga Newsdesk
ALX Oncology Holdings Announces Publication Of Clinical Data From Its ASPEN-06 Randomized Phase 2 Clinical Trial In Nature Medicine, Showing Durable Clinical Benefit With Evorpacept In HER2-Positive Gastric Cancer
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained
ALXO
BenzingaAug 6, 2026, 12:39 PMBenzinga Newsdesk
ALX Oncology Holdings Q2 Adj. EPS $(0.11) Beats $(0.14) Estimate
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 75 percent increase over losses of $(0.44) per share
ALXO

8-K filing — ALX ONCOLOGY HOLDINGS INC (ALXO)

Connected Markets

Related Headlines

ALX Oncology Holdings Announces Publication Of Clinical Data From Its ASPEN-06 Randomized Phase 2 Clinical Trial In Nature Medicine, Showing Durable Clinical Benefit With Evorpacept In HER2-Positive Gastric Cancer

ALX Oncology Holdings Q2 Adj. EPS $(0.11) Beats $(0.14) Estimate